Traws Pharma shares fell after UK regulators deferred a planned influenza challenge study for tivoxavir marboxil, delaying clinical development.
Importance Rank:
1
Traws Pharma shares fell after UK regulators deferred a planned influenza challenge study for tivoxavir marboxil, delaying clinical development.
The UCW Newswire : Financial, Business and Tech NewsCopyright © Louis Velazquez. All Rights Reserved.